disord
portal
venou
pressur
portal
hypertens
conceptu
use
hydraul
deriv
ohm
law
pressur
flow
resist
compos
variabl
ground
basic
vascular
biolog
initi
portal
hypertens
develop
result
increas
intrahepat
vascular
resist
commonli
caus
chronic
liver
diseas
lead
multipl
patholog
event
sinusoid
circul
structur
distort
fibrosi
microvascular
thrombosi
dysfunct
liver
sinusoid
endotheli
cell
lsec
hepat
stellat
cell
hsc
activ
basic
mechan
lsec
hsc
dysregul
extens
explor
clarif
role
microvascular
thrombosi
platelet
function
pathogenesi
portal
hypertens
lag
behind
secondari
event
portal
hypertens
lead
splanchnic
system
arteri
vasodil
contribut
increas
splanchnic
blood
flow
liver
increas
portal
pressur
despit
collater
format
excess
vasodil
mesenter
arteri
facilit
hyperdynam
circul
along
increas
blood
flow
portosystem
collater
result
clinic
devast
complic
includ
gastroesophag
varic
varic
hemorrhag
hepat
encephalopathi
format
portosystem
shunt
ascit
renal
failur
due
hepatoren
syndrom
review
articl
discuss
follow
topic
mechan
sinusoid
portal
hypertens
focus
hsc
lsec
biolog
patholog
angiogenesi
role
microvascular
thrombosi
platelet
mesenter
vasculatur
portal
hypertens
futur
direct
vascular
biolog
research
portal
hypertens
hepat
fibrosi
first
factor
consid
explain
increas
resist
cirrhot
liver
classic
paper
bhathal
grossman
demonstr
vasodil
challeng
anim
model
cirrhosi
increas
resist
portal
flow
due
architectur
distort
cirrhot
liver
due
revers
hypercontractil
phenotyp
complet
examin
pathobiolog
hepat
fibrosi
outsid
scope
review
area
liver
diseas
constant
excit
new
advanc
key
pathway
fibrosi
liver
proinflammatori
signal
caus
activ
hsc
therebi
lead
extracellular
matrix
deposit
recent
review
expert
field
understand
pathway
led
turn
understand
revers
regress
fibrosi
hold
great
therapeut
potenti
chronic
liver
diseas
portal
hypertens
hepat
stellat
cell
hsc
posit
space
diss
thu
thought
play
anoth
role
portal
hypertens
beyond
fibrosi
possibl
hepat
pericyt
perivascular
nonendotheli
cell
myriad
function
includ
regul
flow
smooth
musclelik
contractil
format
extracellular
matrix
regul
endotheli
prolifer
observ
aris
work
demonstr
hsc
activ
acquir
myofibroblastlik
phenotyp
acquisit
alphasmooth
muscl
actin
respons
liver
injuri
well
exhibit
contractil
phenotyp
shown
gel
contract
assay
use
activ
hsc
rat
model
toxic
liver
injuri
thu
hsc
perivascular
contract
thought
key
contributor
dynam
revers
compon
portal
hypertens
cirrhosi
key
pathway
regul
hsc
contractil
phenotyp
endothelin
signal
endothelin
bind
gprotein
coupl
receptor
endothelin
eta
endothelin
b
etb
typic
found
vascular
smooth
muscl
cell
endotheli
cell
respect
major
subtyp
relev
liver
diseas
preferenti
bound
eta
two
subtyp
level
protein
elev
set
liver
injuri
along
messeng
rna
mrna
demonstr
increas
product
set
wherea
normal
liver
endotheli
cell
produc
major
liver
injuri
shift
product
primarili
hsc
also
markedli
upregul
eta
etb
receptor
suggest
increas
sensit
signal
shown
induc
contract
sinusoid
vasculatur
antagon
eta
shown
reduc
portal
pressur
cirrhot
anim
model
studi
mechan
hsc
contract
yield
insight
function
pathway
increas
intracellular
calcium
lead
myosin
light
chain
kinas
activ
myosin
light
chain
phosphoryl
via
rhokinas
protein
kinas
c
pathway
lead
inhibit
myosin
light
chain
dephosphoryl
myosin
light
chain
phosphatas
enhanc
calcium
sensit
mechan
hsc
contract
elucid
well
includ
cxc
chemokin
receptor
express
activ
stellat
cell
chemokin
cxc
motif
ligand
bind
lead
increas
myosin
light
chain
phosphoryl
contractil
rho
kinasedepend
manner
revers
rho
kinas
inhibitor
anoth
interest
recent
find
ammonia
may
play
direct
role
hsc
contractil
hsc
expos
ammonia
demonstr
contractil
phenotyp
control
gel
contract
assay
produc
higher
level
myosin
iia
import
contract
dosedepend
manner
preclin
data
also
emerg
role
relaxin
receptor
reduc
hsc
contract
portal
pressur
recent
studi
also
point
role
farnesoid
x
receptor
fxr
regul
endothelin
pathway
hsc
contractil
demonstr
fxr
stimul
decreas
level
phosphoryl
moesin
biochem
marker
hsc
contractil
well
portal
pressur
anim
model
cirrhosi
portal
hypertens
though
exact
mechan
uncertain
liver
sinusoid
endotheli
cell
lsec
distinct
endotheli
cell
elsewher
liver
well
elsewher
bodi
distinguish
featur
fenestr
fenestra
measur
approxim
micron
organ
group
siev
plate
thought
facilit
transport
macromolecul
hepat
sinusoid
space
diss
interact
hepatocyt
anoth
characterist
set
lsec
apart
endotheli
cell
organ
lack
basement
membran
maxim
permeabl
lumen
sinusoid
space
diss
lsec
lose
fenestra
develop
basement
membran
consequ
liver
fibrosi
becom
capillar
vascular
endotheli
growth
factor
vegf
shown
key
factor
maintain
endotheli
fenestra
increas
concentr
molecul
increas
poros
lsec
vegf
signal
necessari
maintain
lsec
phenotyp
mainten
fenestra
without
basement
membran
thought
come
hsc
hepatocyt
sinc
cocultur
hsc
hepatocyt
restor
phenotyp
lost
antivegf
antibodi
vegf
mainten
normal
lsec
phenotyp
depend
nitric
oxid
product
block
synthas
inhibitor
n
methyl
ester
hydrochlorid
lname
remov
vegf
signal
anim
model
via
transgen
system
liverspecif
secret
solubl
vegf
decoy
receptor
sequest
endogen
vegf
shown
lead
loss
lsec
fenestr
result
portal
hypertens
hsc
activ
independ
hepat
parenchym
damag
revers
portal
hypertens
restor
vegf
addit
composit
collagen
space
diss
may
play
role
mainten
loss
endotheli
cell
fenestr
role
lipid
raft
regul
fenestr
also
elucid
util
superresolut
fluoresc
microscopi
research
recent
demonstr
invers
relationship
area
endotheli
cell
lipid
raft
area
membran
fenestr
addit
shown
inhibit
lipid
raft
format
via
actin
disrupt
increas
fenestr
increas
raft
format
low
concentr
triton
decreas
fenestr
commun
lsec
hsc
import
pathogenesi
portal
hypertens
evidenc
fact
loss
lsec
phenotyp
permiss
hsc
activ
research
lsec
hsc
commun
demonstr
isoform
fibronectin
produc
lsec
bile
duct
ligat
model
liver
damag
abl
activ
hsc
though
subsequ
studi
reveal
factor
import
hsc
motil
differenti
myofibroblast
phenotyp
recent
literatur
also
reveal
mechan
lsec
commun
hsc
signal
via
exosom
contain
sphingosin
product
phosphat
provid
signal
hsc
migrat
close
tie
activ
phenotyp
convers
lsec
signal
also
respons
mainten
hsc
quiescenc
lsec
induct
hsc
deactiv
shown
possibl
via
paracrin
signal
via
kruppellik
factor
cyclas
pathway
endotheli
cell
variou
pathway
lsechsc
crosstalk
depict
fig
nitric
oxid
produc
lsec
play
direct
role
regul
vascular
tone
liver
discuss
also
play
key
role
lsechsc
crosstalk
lsec
abl
induc
hsc
revers
activ
quiescenc
via
nodepend
mechan
may
relev
diseas
alcohol
liver
injuri
nonalcohol
fatti
liver
diseas
loss
normal
lsec
phenotyp
shown
occur
fibrosi
studi
relev
nodepend
mechan
shown
donor
abl
inhibit
prolifer
chemotaxi
activ
hsc
respons
plateletderiv
growth
factor
disrupt
intracellular
signal
pathway
via
prostaglandin
effect
inhibit
hsc
migrat
via
cyclic
guanosin
monophosph
cgmp
depend
protein
kinas
pkg
mediat
inhibit
pathway
nitric
oxid
signal
also
shown
induc
hsc
apoptosi
via
caspaseindepend
mechan
possibl
relat
increas
mitochondri
oxid
stress
increas
mitochondri
membran
permeabl
along
possibl
lysosom
stress
compon
nitric
oxid
crucial
import
regul
normal
hepat
vascular
tone
portal
pressur
sourc
hepat
vasculatur
lsec
endotheli
cell
blood
vessel
cell
express
endotheli
nitric
oxid
synthas
eno
produc
baselin
level
product
increas
respons
flow
also
upregul
vegf
studi
demonstr
although
lsec
cirrhot
liver
contain
similar
amount
eno
normal
liver
dysfunct
patholog
condit
diminish
releas
diseas
addit
lsec
cirrhosi
diminish
abil
respond
increas
flow
increas
product
compar
healthi
state
derang
lead
impair
vasodil
hepat
microcircul
cirrhosi
import
contributor
sinusoid
portal
hypertens
regul
eno
function
involv
multipl
player
act
concert
stimulatori
signal
found
occur
via
phosphoryl
protein
kinas
akt
subsequ
work
elucid
gprotein
coupledreceptor
kinas
facilit
aktdepend
eno
activ
function
eno
may
also
inhibit
bind
interact
turn
disrupt
calmodulin
endotheli
dysfunct
lead
increas
resist
sinusoid
microcircul
promot
activ
hsc
pharmacolog
approach
revers
dysfunct
lsec
phenotyp
could
effect
therapeut
strategi
emerg
exampl
use
statin
studi
shown
statin
amelior
portal
hypertens
cirrhot
patient
experiment
model
portal
hypertens
studi
demonstr
statin
improv
endotheli
dysfunct
increas
bioavail
sinusoid
microcircul
sever
candid
mechan
observ
effect
propos
one
abil
statin
inhibit
synthesi
isoprenoid
necessari
membran
anchor
activ
small
guanin
triphosphatas
gtpase
rhoa
given
rhoarhokinas
signal
could
downregul
eno
activ
express
statin
decreas
rhoa
activ
could
enhanc
bioavail
decreas
intrahepat
vascular
resist
anoth
potenti
mechan
statin
increas
activ
aktprotein
kinas
b
phosphoryl
activ
eno
therebi
increas
bioavail
addit
reduc
endotheli
cell
dysfunct
statin
could
target
rhoarhokinas
pathway
pericyt
eg
activ
hsc
decreas
contractil
phenotyp
therebi
lower
intrahepat
resist
reduc
portal
hypertens
angiogenesi
process
new
blood
vessel
format
preexist
vascular
bed
implic
portal
hypertens
well
hepat
angiogenesi
could
caus
irregular
intrahepat
circulatori
rout
thu
could
increas
intrahepat
resist
patholog
angiogenesi
splanchnic
circul
thought
worsen
portal
hypertens
increas
vasculatur
creat
via
angiogenesi
could
enhanc
blood
flow
portal
venou
system
therebi
increas
portal
pressur
block
patholog
angiogenesi
kinas
inhibitor
sorafenib
sunitinib
imatinib
pioglitazon
combin
gleevec
rapamycin
shown
amelior
portal
hypertens
experiment
model
addit
signal
pathway
known
import
endotheli
cell
differenti
vascular
develop
shown
import
portal
hypertens
knockout
pathway
liver
lead
nodular
regen
hyperplasia
nrh
common
caus
noncirrhot
portal
hypertens
interestingli
knockout
anim
develop
portal
hypertens
even
onset
nrh
thought
caus
disord
intrahepat
vasculatur
angiogenesi
also
shown
associ
fibrosi
progress
liver
although
relationship
complex
could
caus
correl
due
hypoxia
modul
angiogenesi
predict
effect
liver
fibrosi
studi
intrahepat
portal
hypertens
evolv
includ
studi
platelet
thrombosi
import
contributor
pathophysiolog
ian
wanless
other
instrument
contributor
area
observ
term
parenchym
extinct
account
fibrosi
progress
due
intrahepat
vascular
thrombosi
though
cirrhosi
previous
felt
confer
bleed
tendenc
advanc
physiolog
test
assess
coagul
statu
systemat
studi
bleed
complic
led
grow
consensu
hemostat
statu
cirrhosi
delic
rebalanc
perhap
even
prothrombot
observ
set
stage
explor
role
thrombosi
sinusoid
portal
hypertens
anim
studi
lend
support
import
thrombosi
fibrosi
progress
portal
hypertens
earli
studi
util
mice
suscept
genet
background
infect
murin
hepat
viru
rna
coronaviru
caus
spectrum
liver
diseas
includ
fulmin
hepat
failur
mice
exhibit
thrombi
hepat
microvasculatur
concord
viral
liver
injuri
suggest
link
sinusoid
thrombosismicrovascular
blockag
liver
damag
support
studi
anim
studi
use
model
carbon
tetrachlorid
induc
liver
damag
demonstr
sinusoid
deposit
fibrinfibrinogen
fibronectin
damag
liver
shortterm
deposit
fibrou
septa
longterm
liver
damag
lead
hypothesi
clot
import
step
fibrot
respons
liver
mechanist
preclin
studi
administ
novel
thrombin
antagonist
model
shown
decreas
liver
fibrosi
mice
defici
prothrombinas
respons
cleav
prothrombin
thrombin
ultim
deposit
fibrin
pathway
reduc
fibrin
deposit
necrosi
model
viral
hepat
lowmolecularweight
heparin
anticoagul
studi
shown
reduc
fibrosi
bile
duct
ligat
model
thioacetamid
model
aspirin
also
shown
reduc
fibrosi
model
hepat
fibrosi
model
factor
v
leiden
homozyg
mice
hepat
fibrosi
wildtyp
mice
anticoagul
warfarin
reduc
hepat
fibrosi
wildtyp
mice
compar
control
notabl
studi
warfarin
treatment
antifibrot
effect
factor
v
leiden
homozyg
mice
author
specul
dose
adequ
overcom
profibrot
phenotyp
recent
studi
mechanist
link
portal
hypertens
hepat
sinusoid
thrombosi
fibrosi
inferior
vena
cava
ivc
ligat
model
posthepat
portal
hypertens
result
sinusoid
thrombosi
hepat
fibrosi
amelior
pharmacolog
treatment
warfarin
genet
inhibit
clot
cascad
fibrin
shown
promot
extracellular
matrix
deposit
hsc
import
recent
paper
rat
model
liver
injuryfibrosi
thioacetamid
without
enoxaparin
demonstr
reduc
portal
pressur
reduc
hsc
activ
reduc
fibrosi
reduc
fibrin
deposit
treat
anim
compar
control
anim
point
role
anticoagul
reduc
classic
structur
dynam
mechan
portal
hypertens
possibl
via
reduct
thrombosi
rivaroxaban
also
shown
thioacetamid
model
cirrhosi
rat
reduc
portal
pressur
like
combin
reduct
hsc
activ
endotheli
dysfunct
microvascular
thrombosi
rather
fibrosi
platelet
intim
associ
typic
physiolog
vascular
thrombosi
investig
biolog
cirrhosi
emerg
area
care
studi
initi
assess
cirrhot
platelet
dysfunct
predispos
patient
bleed
tendenc
recent
howev
investig
found
activ
cirrhot
platelet
hemostasi
thrombosi
potenti
preserv
even
increas
although
conflict
data
recent
review
function
platelet
variou
type
liver
injuri
quit
complex
multipl
situationspecif
factor
determin
whether
platelet
play
profibrot
role
versu
antifibrot
proregen
role
particular
relev
portal
hypertens
plateletderiv
serotonin
model
viral
hepat
result
hepat
microcirculatori
dysfunct
sinusoid
lead
reduc
flow
consist
studi
demonstr
serotoninmedi
low
sinusoid
flow
revers
serotonin
receptor
antagon
effect
may
mediat
serotonininduc
calcium
influx
sinusoid
endotheli
cell
myosin
light
chain
phosphoryl
caus
fenestr
contract
serotoninmedi
hsc
activ
possibl
increas
intracellular
calcium
given
nonalcohol
steatohepat
nash
associ
metabol
syndrom
associ
platelet
dysfunct
result
hypercoagul
platelet
increas
express
glycoprotein
gp
iibiiia
receptor
resist
antiaggreg
stimuli
prostaglandin
platelet
function
diseas
particular
interest
anim
model
nash
antiplatelet
drug
aspirin
ticlopidin
thienopyridin
adenosin
diphosph
receptor
antagonist
cilostazol
phosphodiesteras
iii
inhibitor
found
reduc
hepat
steatosi
inflamm
fibrosi
cilostazol
also
led
increas
eno
product
measur
mrna
express
howev
cilostazol
largest
antifibrot
effect
postul
impact
lipid
glucos
metabol
addit
antiplatelet
activ
observ
may
entir
antithrombot
effect
put
role
platelet
thrombosi
portal
hypertens
shown
schemat
fig
futur
experiment
clinic
trial
continu
expand
knowledg
regard
thrombosi
cirrhot
platelet
biolog
portal
hypertens
particular
ongo
multicent
prospect
random
trial
effect
rivaroxaban
direct
factor
xa
inhibitor
surviv
develop
complic
portal
hypertens
patient
cirrhosi
cirroxaban
provid
evid
effect
anticoagul
alter
cours
cirrhosi
portal
hypertens
clinicaltrialsgov
antithrombot
antiplatelet
drug
shown
role
amelior
portal
hypertens
fibrosi
hepat
decompens
depict
along
site
action
coagul
cascad
fig
addit
liver
vasculatur
mesenter
vasculatur
play
key
role
portal
hypertens
foundat
understand
physiolog
vascular
bed
come
classic
studi
groszmann
other
demonstr
even
develop
portosystem
collater
splenchnic
circul
hyperdynam
portal
hypertens
accordingli
portal
pressur
remain
elev
due
increas
splanchnic
flow
liver
excess
vasodil
splanchnic
arteri
mediat
overproduct
eno
contribut
increas
flow
studi
use
rat
partial
portal
vein
ligat
show
higher
eno
level
increas
product
preced
develop
hyperdynam
circul
vegf
import
mediat
eno
activ
studi
demonstr
higher
eno
activ
lead
overproduct
mesenter
vasculatur
portal
hypertens
via
aktdepend
pathway
lead
eno
phosphoryl
activ
form
eno
mechan
splanchnic
vasodil
occur
cirrhosi
via
convers
angiotensin
ang
ii
ang
subsequ
activ
ma
receptor
pathway
via
carbon
monoxid
prostacyclin
endocannabinoid
adrenomedullin
endotheliumderiv
hyperpolar
factor
play
role
patholog
well
previous
review
arteri
thin
smooth
muscl
hypocontractil
also
promot
disord
physiolog
mesenter
vasculatur
portal
hypertens
impair
sympathet
nervou
system
also
implic
hypocontractil
mesenter
arteri
develop
hyperdynam
circulatori
syndrom
portal
hypertens
rat
anim
exhibit
mesenter
sympathet
nerv
atrophyregress
administr
agent
inhibit
nerv
disord
eg
capsaicin
gambog
amid
amelior
hyperdynam
circulatori
syndrom
impair
neuron
function
also
associ
decreas
releas
neuropeptid
neurotransmitt
potent
vasoconstrictor
produc
sympathet
nervou
system
administr
exogen
neuropeptid
decreas
excess
vasodil
mesenter
arteri
portal
hypertens
rat
indic
hypocontractil
mesenter
arteri
least
part
mediat
impair
product
neural
factor
recent
studi
explor
agent
amelior
hyperdynam
hypocontractil
mesenter
vascular
phenotyp
cirrhosi
use
thalidomid
arginin
vasopressin
receptor
partial
agonist
known
whether
immun
cell
directli
relat
develop
portal
hypertens
howev
sinc
immun
cell
play
import
role
hepat
fibrogenesi
fibrosi
major
caus
portal
hypertens
consid
key
regul
role
macrophag
particularli
noteworthi
macrophag
shown
facilit
hepat
fibrosi
patholog
angiogenesi
fibroticcirrhot
mice
convers
inhibit
macrophag
infiltr
reduc
patholog
event
direct
interact
macrophag
endotheli
cell
also
shown
suggest
paracrin
signal
relationship
fact
lsec
serv
layer
adhes
varieti
resid
immun
cell
popul
express
variou
chemokin
receptor
adhes
molecul
lsec
also
regul
immun
cell
function
phenotyp
cell
differenti
macrophag
polar
portal
hypertens
associ
lsec
dysfunct
could
thu
affect
immun
cell
function
addit
regul
intrahepat
vascular
tone
elucid
lsec
dysfunct
influenc
immun
cell
function
import
advanc
understand
hepat
vascular
biolog
discuss
platelet
biolog
cirrhosi
receiv
increas
attent
becom
area
activ
investig
understand
platelet
function
fibrinolysi
remain
insuffici
studi
defin
coagul
state
cirrhot
patient
need
use
reliabl
methodolog
consider
divers
clinic
present
platelet
adhes
aggreg
critic
step
coagul
thrombosi
key
function
interact
platelet
endotheli
cell
endotheli
cell
produc
potent
inhibitor
platelet
activ
prostacyclin
along
adenosin
diphosphatas
adpas
enzym
decompos
adp
strong
activ
platelet
endotheli
dysfunct
damag
occur
platelet
inhibitori
function
impair
instead
gener
deposit
platelet
adhes
factor
von
willebrand
factor
collagen
fibrinogen
occur
endotheli
cell
surfac
facilit
platelet
adhes
activ
given
lsec
dysfunct
wellknown
condit
liver
cirrhosi
portal
hypertens
interact
lsec
platelet
relat
thrombosi
better
defin
platelet
also
influenc
lsec
function
modul
product
growth
factor
interleukin
il
addit
platelet
produc
transform
growth
factor
beta
potent
factor
caus
endothelialtomesenchym
transit
wealth
biolog
leav
mani
interest
import
question
role
platelet
pathogenesi
liver
cirrhosi
portal
hypertens
especi
regard
interact
lsec
role
lymphat
vessel
liver
larg
unknown
howev
increas
lymphat
vessel
report
liver
fibrosi
idiopath
portal
hypertens
hepatocellular
carcinoma
hcc
suggest
involv
patholog
condit
mani
question
answer
includ
function
signific
vessel
role
promot
mitig
pathogenesi
mechan
lymphangiogenesi
relationship
lymphangiogenesi
hemodynam
elucid
mechan
lymphangiogenesi
associ
portal
hypertens
interest
area
investig
pathogenesi
portal
hypertens
complex
portal
hypertens
involv
hepat
circul
also
hyperdynam
physiolog
system
splanchnic
circul
mani
pathophysiolog
question
remain
explor
includ
role
immun
cell
platelet
lymphat
vascular
system
mention
understand
involv
factor
advanc
knowledg
portal
hypertens
hope
discov
new
therapeut
intervent
